This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Went, P. Th. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Went, P. Th. Articles by Sauter, G. Social Bookmarking                            What's this?

Prevalence of KIT Expression in Human Tumors

From the Institute of Pathology, University of Basel; Novartis Pharma AG, Basel, Switzerland; and Diomeda Life Sciences Inc, Rockville, MD

Address reprint requests to Guido Sauter, MD, Institute of Pathology, University of Basel, Schönbeinstrasse 40, 4031 Basel, Switzerland; e-mail: guido.sauter{at}unibas.ch

PURPOSE: KIT is a target for imatinib mesylate (Gleevec; Novartis Pharma, Basel, Switzerland). Gastrointestinal stromal tumors (GISTs) express KIT and respond favorably to imatinib therapy. To determine other tumors in which such a molecular targeted therapy might be indicated, we investigated KIT expression in different human tumor types. Because recent studies in GISTs suggest that KIT-activating mutations predict response to imatinib therapy, we also sequenced a subset of positive tumors.

MATERIALS AND METHODS: More than 3,000 tumors from more than 120 different tumor categories were analyzed by immunohistochemistry in a tissue microarray format. Seven commercially available anti-KIT antibodies were initially evaluated. The antibody A4502 (DAKO) was selected for analysis because of a high frequency of positivity in GIST and low staining background in other tissues. To determine the frequency of KIT mutations in various tumor types, the exons 2, 8, 9, 11, 13, and 17 (where mutations previously were reported) were sequenced in 36 tumors with strong KIT expression.

RESULTS: KIT positivity was detected in 28 of 28 GISTs (100%), 42 of 50 seminomas (84%), 34 of 52 adenoid-cystic carcinomas (65%), 14 of 39 malignant melanomas (35%), and eight of 47 large-cell carcinomas of the lung (17%), as well as in 47 additional tumor types. KIT mutations were found in six of 12 analyzed GISTs, but only in one of 24 other tumors.

CONCLUSION: The results suggest that KIT expression occurs infrequently in most tumor types and that, with the exception of GISTs, KIT gene mutations are rare in immunohistochemically KIT-positive tumors.

The first two authors contributed equally to this work.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. E. Woodman, J. C. Trent, K. Stemke-Hale, A. J. Lazar, S. Pricl, G. M. Pavan, M. Fermeglia, Y.N. V. Gopal, D. Yang, D. A. Podoloff, et al. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates Mol. Cancer Ther., August 1, 2009; 8(8): 2079 - 2085. [Abstract] [Full Text] [PDF]

				L C B Tong, Z S Kamil, A Al Habeeb, and D Ghazarian Non-melanocytic mimics of melanoma, part II: intradermal mimics J. Clin. Pathol., April 1, 2009; 62(4): 290 - 307. [Abstract] [Full Text] [PDF]

				C. Beadling, E. Jacobson-Dunlop, F. S. Hodi, C. Le, A. Warrick, J. Patterson, A. Town, A. Harlow, F. Cruz III, S. Azar, et al. KIT Gene Mutations and Copy Number in Melanoma Subtypes Clin. Cancer Res., November 1, 2008; 14(21): 6821 - 6828. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., October 1, 2008; 19(10): 1713 - 1719. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, H. Joensuu, G. D. Demetri, C. L. Corless, J. Apperley, J. A. Fletcher, D. Soulieres, S. Dirnhofer, A. Harlow, A. Town, et al. Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases Clin. Cancer Res., May 1, 2008; 14(9): 2717 - 2725. [Abstract] [Full Text] [PDF]

				J. A. Gilbert, M. P. Goetz, C. A. Reynolds, J. N. Ingle, K. F. Giordano, V. J. Suman, H. E. Blair, R. B. Jenkins, W. L. Lingle, M. M. Reinholz, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy Mol. Cancer Ther., April 1, 2008; 7(4): 944 - 951. [Abstract] [Full Text] [PDF]

				R. J Barry, L. R de Moura, J.-C. Marshall, B. F Fernandes, M. E. Orellana, E. Antecka, C. Martins, and M. N Burnier Expression of C-kit in retinoblastoma: a potential therapeutic target Br J Ophthalmol, November 1, 2007; 91(11): 1532 - 1536. [Abstract] [Full Text] [PDF]

				Y. Ali, Y. Lin, M. M. Gharibo, M. K. Gounder, M. N. Stein, T. F. Lagattuta, M. J. Egorin, E. H. Rubin, and E. A. Poplin Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5876 - 5882. [Abstract] [Full Text] [PDF]

				A. Zeuner, M. Signore, D. Martinetti, M. Bartucci, C. Peschle, and R. De Maria Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor Cancer Res., May 15, 2007; 67(10): 4767 - 4773. [Abstract] [Full Text] [PDF]

				J. Lasota, B. Wasag, S. E. Steigen, J. Limon, and M. Miettinen Improved Detection of KIT Exon 11 Duplications in Formalin-Fixed, Paraffin-Embedded Gastrointestinal Stromal Tumors J. Mol. Diagn., February 1, 2007; 9(1): 89 - 94. [Abstract] [Full Text] [PDF]

				A. Zimpfer, S. Schonberg, A. Lugli, C. Agostinelli, S. A Pileri, P. Went, and S. Dirnhofer Construction and validation of a bone marrow tissue microarray J. Clin. Pathol., January 1, 2007; 60(1): 57 - 61. [Abstract] [Full Text] [PDF]

				F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]

				P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]

				T. Ishikubo, K. Akagi, M. Kurosumi, K. Yamaguchi, T. Fujimoto, H. Sakamoto, Y. Tanaka, and A. Ochiai Immunohistochemical and Mutational Analysis of c-kit in Gastrointestinal Neuroendocrine Cell Carcinoma Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 494 - 498. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, G. A. McArthur, G. D. Demetri, H. Joensuu, P. Bono, R. Herrmann, H. Hirte, S. Cresta, D. B. Koslin, C. L. Corless, et al. Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor) J. Clin. Oncol., March 1, 2006; 24(7): 1195 - 1203. [Abstract] [Full Text] [PDF]

				G. F. Arroyo, G. Acosta, M. Monteros Alvi, E. Raspi, G. V. Almonacid, H. Fabian, and M. F. Freire Prevalence of KIT Expression in Human Tumors: Gallbladder Cancer J. Clin. Oncol., August 1, 2005; 23(22): 5268 - 5271. [Full Text] [PDF]

				G. Sauter, R. Simon, K. Al-Kuraya, and L. Terracciano In Reply: J. Clin. Oncol., August 1, 2005; 23(22): 5271 - 5272. [Full Text] [PDF]

				C. Serrano, C. Mackintosh, D. Herrero, A. S. Martins, T. Hernandez, J. Perez-Fontan, A. Perez, E. Serrano, A. Orfao, A. Bullon, et al. Imatinib Is Not a Potential Alternative Treatment for Uterine Leiomyosarcoma Clin. Cancer Res., July 1, 2005; 11(13): 4977 - 4981. [Full Text] [PDF]